Canakinumab
CANTOS: Canakinumab reduces total CV events in patients at high inflammatory risk
Canakinumab reduced total CV events in patients with prior MI and residual inflammatory risk, according to new data from the CANTOS trial.
Canakinumab may reduce total knee, hip replacement, OA symptoms
Interleukin-1 inhibition with canakinumab may substantially reduce rates of total hip and knee replacement, as well as osteoarthritis symptoms, according to data published in the Annals of Internal Medicine.
Tapering canakinumab feasible in patients with juvenile arthritis who achieve remission
Tapering canakinumab in patients with systemic juvenile idiopathic arthritis who achieve remission may be feasible but holding this response may require consistent IL-1 inhibition, according to data published in Arthritis & Rheumatology.
Anti-inflammatory agents may have potential in secondary prevention
Atherosclerotic CVD has long been recognized as an inflammatory disease.
Canakinumab improves systemic juvenile idiopathic arthritis regardless of fever
Treatment with canakinumab resulted in rapid, sustained improvements in active systemic juvenile idiopathic arthritis, regardless of whether the patient had a fever at initiation, according to data published in Arthritis & Rheumatology.
Ruling out mimics for systemic onset JIA often requires 'extensive workup'
A quotidian fever lasting at least 2 weeks is one of the hallmarks of systemic onset juvenile idiopathic arthritis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.
FDA approves Ilaris injection for active, adult-onset Still's disease
The FDA has approved Novartis’ Ilaris injection for the treatment of active and adult-onset Still’s disease, according to a press release.